Revvity, Inc.
Financials
Valuation Metrics
Revvity, Inc.'s Market Cap is $17.51B. At end of 2025 it was $10.95B. Ranked #640 of 3,118 in US market (top 21%), #440 of 1,644 on NYSE (top 27%), #45 of 203 in Health Care Equipment & Services (top 22%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $17.51B | US#640/3,118 Sec#45/203 |
| Revenue | $2.91B | US#1,204/3,118 Sec#74/203 |
| Net Income | $238M | US#1,199/3,118 Sec#60/203 |
| Total Assets | $12.05B | US#881/3,118 Sec#42/203 |
| Net Assets | $7.23B | US#538/3,118 Sec#31/203 |
| Employees | 11,000 | US#810/3,118 Sec#62/203 |
| Value | ||
| P/E | 73.73x | US#2,022/3,118 Sec#106/203 |
| P/B | 2.42x | US#1,521/3,118 Sec#69/203 |
| P/S | 6.02x | US#2,429/3,118 Sec#158/203 |
| EV/EBITDA | 25.86x | US#2,121/3,118 Sec#104/203 |
| FCF Yield | 3.19% | US#1,773/3,118 Sec#100/203 |
| Profitability | ||
| ROE | 3.29% | US#1,936/3,118 Sec#101/203 |
| ROA | 1.97% | US#1,641/3,118 Sec#102/203 |
| Op. Margin | 12.32% | US#1,394/3,118 Sec#60/203 |
| Revenue Growth | 4.05% | US#1,862/3,118 Sec#140/203 |
| Earnings Growth | -17.07% | US#1,514/3,118 Sec#80/203 |
| Financial Health | ||
| Debt Ratio | 66.64% | US#731/3,118 Sec#79/203 |
| Total Debt | $3.34B | US#880/3,118 Sec#40/203 |
| FCF | $559M | US#844/3,118 Sec#48/203 |
| Cash | $1.02B | US#675/3,118 Sec#38/203 |
| Current Ratio | 1.80x | US#1,364/3,118 Sec#120/203 |
| Net Debt/EBITDA | 3.02x | US#1,628/3,118 Sec#103/203 |
| Dividend | ||
| Div. Yield | 0.18% | US#1,651/3,118 Sec#52/203 |
| Div. Growth | 3.21% | US#954/3,118 Sec#35/203 |
| Performance | ||
| 1Y Return | 72.59% | US#284/3,118 Sec#32/203 |
| 1M Return | 2.69% | US#1,505/3,118 Sec#122/203 |
| From 52W High | -7.13% | US#593/3,118 Sec#57/203 |
| 1Y MDD | -30.14% | US#1,311/3,118 Sec#65/203 |
| Trading | ||
| Volume | 2,660,750 shares | US#738/3,118 Sec#40/203 |
| Trading Value | $423M | US#284/3,118 Sec#26/203 |
| Per Share | ||
| EPS | $2.13 | US#1,296/3,118 Sec#66/203 |
| BPS | $64.80 | US#278/3,118 Sec#21/203 |
Company Info
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.